Gazette
masthead
   About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University December 18, 2006 | Vol. 36 No. 15
 
Drug Treatment Slows Macular Vision Loss in Diabetics

By Jeff Ventura
Johns Hopkins Medicine

A drug commonly used to slow the loss of central vision has shown promise in stemming a common precursor of blindness in diabetics, which involves the same central light-sensitive area of the retina, Johns Hopkins Wilmer Eye Institute scientists report.

Encouraged by the effect of ranibuzumab in people with macular degeneration, the Johns Hopkins researchers injected the drug into the eyes of 10 people losing their sight from macular edema, one of many complications of diabetes and a first stage of diabetic retinopathy.

Over the course of several months of therapy, every patient in the preliminary Johns Hopkins study could read at least two more lines on the standard eye chart, the researchers said. Moreover, the thickness of the patients' maculae, the central part of the retina responsible for seeing fine details, decreased an average of 85 percent. The American Journal of Ophthalmology published the team's findings in the December issue.

Quan Dong Nguyen, an assistant professor of ophthalmology at the Wilmer Eye Institute, said, "The results are impressive, although we will not know until we begin a larger clinical trial what the long-term benefits of the drug might be."

The Johns Hopkins group believes that ranibuzumab interferes with a protein that spurs the growth of unwanted blood vessels in the back of the eye. Vascular endothelial growth factor, or VEGF, is released when the oxygen supply in the eye is restricted by blood vessel damage related to diabetes.

In a self-preserving attempt to acquire more oxygen, the VEGF signals for the creation of new blood vessels, which almost always damage vision, rather than improve it, by blocking light's entry onto the retina.

"We've suspected for a while that ranibuzumab's ability to shut down VEGF's signaling would do the trick because it's highly likely that VEGF is the culprit when it comes to diabetic macular edema," Nguyen said.

More than 4 million diabetics in the United States have diabetic retinopathy, and, according to the National Eye Institute, one in 12 of those experience at least some vision loss.

Macular edema, a first stage of retinopathy, occurs when, over time, excess uncontrolled blood sugar damages the tiny blood vessels in the eye, causing fluid and fat to leak onto the retina at the back of the eye. The swelling interferes with focus and blurs vision. Making matters worse, a lack of oxygen often then triggers VEGF's production cycle.

All 10 subjects in the study had some vision loss at the start of the clinical trial, in which ranibuzumab was administered at the one-, two-, four- and six-month marks. The thickness of each patient's macula was measured at each point in the study using an advanced digital imaging technique.

"Within a week, several patients experienced dramatic reductions in the thickness of their maculas, and there were further improvements with each injection," said Peter Campochiaro, the Dolores and George Eccles Professor of Ophthalmology at the School of Medicine, who is also an investigator in the study.

Ranibuzumab is marketed for treatment of neovascular macular degeneration by Genentech under the brand name Lucentis.

GO TO DECEMBER 18, 2006 TABLE OF CONTENTS.
GO TO THE GAZETTE FRONT PAGE.


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 | gazette@jhu.edu